wb777.co

NEW YORK (AP) — Geronimo Rubio De La Rosa scored 27 points as Columbia beat Fairfield 85-72 on Saturday night. De La Rosa shot 8 of 15 from the field, including 5 for 11 from 3-point range, and went 6 for 6 from the line for the Lions (11-1). Avery Brown shot 5 of 8 from the field and 5 of 5 from the free-throw line to add 16 points. Kenny Noland went 5 of 12 from the field (3 for 7 from 3-point range) to finish with 15 points. The Stags (5-8, 1-1 Metro Atlantic Athletic Conference) were led by Louis Bleechmore, who recorded 12 points. Fairfield also got 12 points and seven assists from Jamie Bergens. Deon Perry had 12 points and five assists. Columbia's next game is Monday against Rutgers on the road, and Fairfield visits Merrimack on Friday. The Associated Press created this story using technology provided by Data Skrive and data from Sportradar .India-Singapore joint military exercise concludesUS stocks are trading near their records as Wall Street takes Donald Trump’s latest talk about tariffs in stride, even if they could roil the global economy were they to take effect. The S&P 500 rose 0.3 per cent in morning trading and was on track to squeak past its all-time high set a couple of weeks ago. The Dow Jones lost 270 points, or 0.6 per cent, from its own record set the day before, while the Nasdaq composite was 0.6 per cent higher. Wall Street has climbed despite Donald Trump’s tariffs threat. Credit: AP The Australian sharemarket is set to climb, with futures at 5.02am AEDT pointing to a rise of 41 points, or 0.5 per cent, at the open. The ASX lost 0.7 per cent on Tuesday. The Australian dollar lost ground. It was 0.8 per cent lower at 64.53 US cents at 5.13am AEDT. Stock markets abroad were down, but mostly only modestly, after President-elect Trump said he plans to impose sweeping new tariffs on Mexico, Canada and China as soon as he takes office. Stock indexes were down 0.1 per cent in Shanghai and nearly flat in Hong Kong, while Canada’s main index was down 0.4 per cent. Trump has often praised the use of tariffs, but investors are weighing whether his latest threat will actually become policy or is just an opening point for negotiations. For now, the market seems to be taking it more as the latter. Unless the United States can prepare alternatives for the autos, energy products and other goods that come from Mexico, Canada and China, such tariffs would raise the price of imported items all at once and make households poorer, according to Carl Weinberg and Rubeela Farooqi, economists at High Frequency Economics. They would also hurt profit margins for US companies, while raising the threat of retaliatory tariffs by other countries. Loading General Motors sank 7.3 per cent, and Ford Motor fell 1.8 per cent. Constellation Brands, which sells Modelo and other Mexican beers in the United States, dropped 4.4 per cent. Beyond the pain such tariffs would cause US households and businesses, they could also push the Federal Reserve to slow or even halt its cuts to interest rates. The Fed had just begun cutting its main interest rate from a two-decade high a couple of months ago to offer support to the job market. While lower interest rates can boost the overall economy and prices for investments, they can also offer more fuel for inflation. Unlike tariffs in Trump’s first term, his proposal from Monday night would affect products across the board. Trump’s tariff talk came almost immediately after US stocks rose Monday amid excitement about his pick for Treasury secretary, Scott Bessent. The hope was the hedge-fund manager could steer Trump away from policies that balloon the US government deficit, which is how much more it spends than it takes in through taxes and other revenue. The talk about tariffs overshadowed another set of mixed profit reports from US retailers that answered few questions about how much more shoppers can keep spending. They’ll need to stay resilient after helping the economy avoid a recession, despite the high interest rates instituted by the Fed to get inflation under control. Kohl’s tumbled 20.4 per cent after its results for the latest quarter fell short of analysts’ expectations. CEO Tom Kingsbury said sales remain soft for apparel and footwear, which helped drag its revenue lower. Kingsbury said a day earlier that he plans to step down as CEO in January. Ashley Buchanan, CEO of Michaels and a retail veteran, will replace him. Best Buy fell 8 per cent after likewise falling short of analysts’ expectations. Dick’s Sporting Goods topped forecasts for the latest quarter thanks to a strong back-to-school season, but its stock lost an early gain to fall 2.4 per cent. A report on Tuesday from the Conference Board said confidence among US consumers improved in November, but not by as much as economists expected. Loading J.M. Smucker jumped 7.6 per cent for one of the biggest gains in the S&P 500 after topping analysts’ expectations for the latest quarter. CEO Mark Smucker credited strength for its Uncrustables, Meow Mix, Café Bustelo and Jif brands. Big Tech stocks also helped prop up US indexes. Gains of 2.7 per cent for Amazon and 1.9 per cent for Microsoft were two of the strongest forces lifting the S&P 500. In the bond market, Treasury yields rose following their big drop from a day before driven by relief following Trump’s pick for Treasury secretary. The yield on the 10-year Treasury climbed to 4.31 per cent from 4.28 per cent late Monday, but it’s still well below the 4.41 per cent level where it ended last week. In the crypto market, bitcoin continued to pull back after topping $US99,000 for the first time late last week. It’s since dipped back toward $US93,400, according to CoinDesk. It’s a sharp turnaround from the bonanza that had earlier taken over the crypto market following Trump’s election. That boom had also appeared to have spilled over into some corners of the stock market. Strategists at Barclays Capital pointed to stocks of unprofitable companies, along with other areas that can be caught up in bursts of optimism by smaller-pocketed “retail” investors. AP The Market Recap newsletter is a wrap of the day’s trading. Get it each we e kday afternoon . Save Log in , register or subscribe to save articles for later. World markets Wall Street Shares Most Viewed in Business Loadingwb777.co 。

The Hopedale food bank is running dry. Calls for donations are with growing demandEngland manager Sarina Wiegman has demanded her team continue to push on after their 0-0 draw with the women's national team (USWNT) at Wembley on Saturday, but praised their defensive effort. The USWNT's head coach Emma Hayes came away from Wembley believing her team should have won the match as they had the bulk of possession and chances. For Wiegman, she saw this as an improved performance after they lost their last match at Wembley to in October. "This shows where we are at and we need to keep improving," Wiegman told ITV. "It is November now. This is good but we want to be better again. We have to be better again." As build momentum towards the Euros next summer, they are still in the process of evolving. Wiegman said she was pleased with their defensive effort, given they had kept just four clean sheets in their previous 19 matches heading into Saturday's match with the reigning Olympic champions. "I thought it was a very intense game," Wiegman said. "Of course we know the USWNT is very dynamic [and] explosive in going forward. Our defence was solid, we were defending as a team, very strong. They challenged us on the wings, I think we solved that well and in the box, we defended that pretty good. "In possession, the first half we wanted to keep the ball better ... Sometimes we'd get out of the press and lose the ball quickly. Second half we got momentum and we did better and both teams were going for the win, so I don't think it was boring [for the fans]. I'm happy with the team performance." Wiegman said the team went into the match wanting to press more than they had in the past, but they had to work for it to click against the USWNT. She handed and starts against the USWNT, and restored in goal. Earps was arguably England's star performer as she kept the USWNT at bay, and she said post-match she was pleased with the team's performance as they look to end a tricky 2024 on a high. "I think it has been a tough year," Earps told ITV. "A few tough results. We know what we can do as a group. It is about figuring out how we can play. "That's the thing with friendlies, you can experiment with a few things. Drawing against the Olympic champions is no small thing but we want to be winning those games."

Century-old department store Nordstrom has agreed to be acquired and taken private by Nordstrom family members and a Mexican retail group in a $6.25 billion deal with the industry being squeezed by discount chains and other competition. Public companies are under a lot more scrutiny and if private, the Nordstrom may have more leeway in reviving a department store chain that has been attempting to reinvigorate sales for years. Javascript is required for you to be able to read premium content. Please enable it in your browser settings. Get our free email newsletters — latest headlines and e-edition notifications.NoneIntech Investment Management LLC acquired a new stake in shares of Ready Capital Co. ( NYSE:RC – Free Report ) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 95,660 shares of the real estate investment trust’s stock, valued at approximately $730,000. Intech Investment Management LLC owned 0.06% of Ready Capital at the end of the most recent quarter. Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Janus Henderson Group PLC lifted its holdings in Ready Capital by 131.0% during the first quarter. Janus Henderson Group PLC now owns 168,496 shares of the real estate investment trust’s stock valued at $1,539,000 after purchasing an additional 95,562 shares in the last quarter. Clear Harbor Asset Management LLC lifted its stake in shares of Ready Capital by 84.0% during the 3rd quarter. Clear Harbor Asset Management LLC now owns 1,440,250 shares of the real estate investment trust’s stock valued at $10,989,000 after buying an additional 657,465 shares in the last quarter. Wolverine Asset Management LLC boosted its holdings in Ready Capital by 2,902.2% in the 3rd quarter. Wolverine Asset Management LLC now owns 402,291 shares of the real estate investment trust’s stock worth $3,069,000 after buying an additional 388,891 shares during the period. Spire Wealth Management increased its stake in Ready Capital by 1,115.6% in the 2nd quarter. Spire Wealth Management now owns 168,261 shares of the real estate investment trust’s stock worth $1,376,000 after buying an additional 154,419 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its holdings in Ready Capital by 6.4% during the first quarter. Price T Rowe Associates Inc. MD now owns 98,156 shares of the real estate investment trust’s stock valued at $897,000 after acquiring an additional 5,874 shares during the period. 55.87% of the stock is owned by hedge funds and other institutional investors. Wall Street Analysts Forecast Growth A number of equities analysts have recently weighed in on the company. Wedbush reaffirmed a “neutral” rating and issued a $9.00 price objective on shares of Ready Capital in a research note on Monday, August 12th. Piper Sandler reduced their price objective on shares of Ready Capital from $9.50 to $8.00 and set a “neutral” rating on the stock in a research report on Monday, September 16th. Keefe, Bruyette & Woods dropped their target price on shares of Ready Capital from $8.00 to $7.75 and set an “underperform” rating for the company in a research report on Monday, August 12th. Finally, UBS Group reduced their price target on shares of Ready Capital from $8.50 to $7.50 and set a “neutral” rating on the stock in a report on Friday, November 15th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat.com, Ready Capital has a consensus rating of “Hold” and an average price target of $9.04. Ready Capital Trading Down 0.7 % Shares of RC opened at $7.37 on Friday. The stock has a market capitalization of $1.24 billion, a PE ratio of -10.53 and a beta of 1.42. The company’s fifty day moving average is $7.23 and its 200 day moving average is $8.05. The company has a debt-to-equity ratio of 0.54, a quick ratio of 1.67 and a current ratio of 1.67. Ready Capital Co. has a fifty-two week low of $6.65 and a fifty-two week high of $11.67. Ready Capital Cuts Dividend The firm also recently announced a quarterly dividend, which was paid on Thursday, October 31st. Stockholders of record on Monday, September 30th were given a dividend of $0.25 per share. This represents a $1.00 annualized dividend and a dividend yield of 13.57%. The ex-dividend date was Monday, September 30th. Ready Capital’s dividend payout ratio is -142.86%. About Ready Capital ( Free Report ) Ready Capital Corporation operates as a real estate finance company in the United States. It operates through two segments: LMM Commercial Real Estate and Small Business Lending. The company originates, acquires, finances, and services lower-to-middle-market (LLM) commercial real estate loans, small business administration (SBA) loans, residential mortgage loans, construction loans, and mortgage-backed securities collateralized primarily by LLM loans, or other real estate-related investments. Featured Articles Five stocks we like better than Ready Capital Dividend Capture Strategy: What You Need to Know The Latest 13F Filings Are In: See Where Big Money Is Flowing Why Invest in 5G? How to Invest in 5G Stocks 3 Penny Stocks Ready to Break Out in 2025 Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours? FMC, Mosaic, Nutrien: Top Agricultural Stocks With Big Potential Receive News & Ratings for Ready Capital Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ready Capital and related companies with MarketBeat.com's FREE daily email newsletter .

Man kills self over 3.5L loans, FIR on creditorsNone

MIAMI — As her students finished their online exam, Arlet Lara got up to make a . Her 16-year-old son found her on the kitchen floor. First, he called Dad in a panic. Then 911. “I had a stroke and my life made a 180-degree turn,” Lara told the Miami Herald, recalling the medical scare she experienced in May 2020 in the early months of the COVID pandemic. “The stroke affected my left side of the body,” the North Miami woman and former high school math teacher said. Lara, an avid runner and gym goer, couldn’t even walk. “It was hard,” the 50-year-old mom said. After years of rehabilitation therapy and a foot surgery, Lara can walk again. But she still struggles with moving. This summer, she became the first patient in South Florida to get an implant of a new and only FDA-approved nerve stimulation device designed to help ischemic stroke survivors regain movement in their arms and hands. This first procedure was at Jackson Memorial Hospital in Miami. Lara’s rehab was at at the Christine E. Lynn Rehabilitation Center for The Miami Project to Cure Paralysis, part of a partnership between Jackson Health System and UHealth. Every year, thousands in the United States , with one occurring every 40 seconds, according to the U.S. Centers for Disease Control and Prevention. The majority of strokes are ischemic, often caused by blood clots that obstruct blood flow to the brain. For survivors, most of whom are left with some level of disability, the Vivistim Paired VNS System, the device implanted in Lara’s chest, could be a game changer in recovery, said Dr. Robert Starke, a UHealth neurosurgeon and interventional neuroradiologist. He also serves as co-director of endovascular neurosurgery at Jackson Memorial Hospital, part of Miami-Dade’s public hospital system. Arlet Lara, the first patient in South Florida to get an FDA-approved nerve stimulation implant, right, runs into her rehabilitation neurology physician Dr. Gemayaret Alvarez, before her physical therapy appointment on Monday, Sept. 9, 2024, at Lynn Rehabilitation Center at Jackson Memorial Hospital. The implant is designed to help stroke survivors regain function in their arms. (Alie Skowronski/Miami Herald/TNS) Arlet Lara, the first patient in South Florida to get an FDA-approved nerve stimulation implant designed to help stroke survivors regain function in their arms, goes through exercises while her therapist activates the device during her physical therapy appointment on Monday, Sept. 9, 2024, at Lynn Rehabilitation Center at Jackson Memorial Hospital. The activation works as positive reinforcement to her muscles when she completes the exercise correctly. (Alie Skowronski/Miami Herald/TNS) Arlet Lara, the first patient in South Florida to get an FDA-approved nerve stimulation implant, does an exercise while Neil Batungbakal, rehabilitation therapist, activates the implant with the black trigger during her physical therapy appointment on Monday, Sept. 9, 2024, at Lynn Rehabilitation Center at Jackson Memorial Hospital. The implant is designed to help stroke survivors regain function in their arms. The activation works as positive reinforcement to her muscles when she completes the exercise correctly. (Alie Skowronski/Miami Herald/TNS) Arlet Lara, the first patient in South Florida to get an FDA- approved nerve stimulation implant, does an exercise while Neil Batungbakal, rehabilitation therapist, activates the implant with the black trigger during her physical therapy appointment on Monday, Sept. 9, 2024, at Lynn Rehabilitation Center at Jackson Memorial Hospital. Arlet Lara, the first patient in South Florida to get an FDA-approved nerve stimulation implant, right, runs into her rehabilitation neurology physician Dr. Gemayaret Alvarez, before her physical therapy appointment on Monday, Sept. 9, 2024, at Lynn Rehabilitation Center at Jackson Memorial Hospital. The implant is designed to help stroke survivors regain function in their arms. (Alie Skowronski/Miami Herald/TNS) The Vivistim Paired VNS System is a small pacemaker-like device implanted in the upper chest and neck area. Patients can go home the same day. The U.S. Food and Drug Administration in 2021 to be used alongside post-ischemic stroke rehabilitation therapy to treat moderate to severe mobility issues in hands and arms. Lara’s occupational therapist can activate the device during rehabilitation sessions to electrically stimulate the vagus nerve, which runs from the brain down to the abdomen and regulates various parts of the body’s nervous system. The electrical stimulation rewires the brain to improve a stroke survivor’s ability to move their arms and hands. Lara also has a magnet she can use to activate the device when she wants to practice at home. Her therapy consists of repetitive tasks, including coloring, pinching cubes and grabbing and releasing cylindrical shapes. After several weeks of rehabilitation therapy with the device, Lara has seen improvement. “Little by little, I’m noticing that my hand is getting stronger. I am already able to brush my teeth with the left hand,” she told the Miami Herald in September. Since then, Lara has finished the initial six-week Vivitism therapy program, and is continuing to use the device in her rehabilitation therapy. She continues to improve and can now eat better with her left hand and can brush her hair with less difficulty, according to her occupational therapist, Neil Batungbakal. Lara learned about the device through an online group for stroke survivors and contacted the company to inquire. She then connected them with her Jackson medical team. Now a year later, the device is available to Jackson patients. So far, four patients have received the implant at Jackson. Starke sees the device as an opportunity to help bring survivors one step closer to regaining full mobility. Strokes are a leading cause of disability worldwide. While most stroke survivors can usually recover some function through treatment and rehabilitation, they tend to hit a “major plateau” after the first six months of recovery, he said. Vivistim, when paired with rehabilitation therapy, could change that. Jackson Health said results of a clinical trial published in the peer-reviewed medical journal in 2021 showed that the device, “when paired with high-repetition, task-specific occupational or physical therapy, helps generate two to three times more hand and arm function for stroke survivors than rehabilitation therapy alone.” The device has even shown to benefit patients 20 years from their original stroke, according to Starke. “So now a lot of these patients that had strokes 10-15 years ago that thought that they would never be able to use their arm in any sort of real functional way are now able to have a real meaningful function, which is pretty tremendous,” Starke said. Vivistim’s vagus-nerve stimulation technology by researchers at the University of Texas at Dallas’ Texas Biomedical Device Center and is being sold commercially by Austin-based MicroTransponder, a company started by university graduates. Similar devices are used to . For Lara, the device is a new tool to help her recovery journey. “Everything becomes a challenge so we are working with small things every day because I want to get back as many functions as possible,” Lara said. Patients interested in Vivistim should speak with their doctor to check their eligibility. The FDA said patients should make sure to discuss any prior medical history, including concurrent forms of brain stimulation, current diathermy treatment, previous brain surgery, depression, respiratory diseases and disorders such as asthma, and cardiac abnormalities. “Adverse events included but were not limited to dysphonia (difficulty speaking), bruising, falling, general hoarseness, general pain, hoarseness after surgery, low mood, muscle pain, fracture, headache, rash, dizziness, throat irritation, urinary tract infection and fatigue,” the FDA said. MicroTransponder says the device is “covered by Medicare, Medicaid, and private insurance with prior authorization on a case-by-case basis.”